Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 2/20 | 0.63 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.63 |
| ▸ | SLC2A2 | P11168 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | TSPO | P30536 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1431027 | 0.84 | KDM4E (0.59) | GABRB2 | |
| SCHEMBL8150 | 0.80 | GABRA2 (0.70) | GABRA2GABRB2SLC2A2NR1I2ABCB11 | |
| SCHEMBL2933100 | 0.79 | SLC2A2 (0.86) | GABRA2GABRB2SLC2A2NR1I2ABCB11 | |
| SCHEMBL7261 | 0.79 | GABRA2 (0.68) | GABRA2GABRB2SLC2A2NR1I2ABCB11 | |
| SCHEMBL19730395 | 0.78 | GABRA2 (0.52) | GABRA2GABRB2SLC2A2 | |
| SCHEMBL1761290 | 0.78 | GABRA1 (0.68) | GABRA2GABRB2NR1I2ABCB11ALB | |
| SCHEMBL1430426 | 0.78 | SLC2A1 (0.59) | GABRA2GABRB2SLC2A2CYP1A2CYP2C9 | |
| SCHEMBL2937747 | 0.77 | LMNA (0.64) | GABRA2GABRB2SLC2A2NR1I2ABCB11 | |
| SCHEMBL19730389 | 0.77 | GABRA2 (0.51) | GABRA2GABRB2SLC2A2NR1I2ABCB11 | |
| SCHEMBL6644305 | 0.77 | TSPO (0.57) | GABRA2GABRB2SLC2A2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2300470-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS GABA-A RECEPTOR MODULATORS | Sepracor Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009143156-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SEPRACOR INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | GABRA2 794/4885GABRB2 1166/4885SLC2A2 1835/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | GABRA2 794/4885GABRB2 1166/4885SLC2A2 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.